# Ipamorelin: Research Overview — Peptide Med Group > A literature summary of ipamorelin, a selective ghrelin-receptor (GHS-R1a) agonist studied for growth-hormone release. Covers mechanism, the one human trial run to date, and cited safety cautions. A selective growth-hormone secretagogue with a clean mechanism and a thin clinical record — the one controlled human trial that exists did not hit its primary endpoint. ## Start here Ipamorelin is a small, lab-made peptide. It binds a receptor in the brain and pituitary gland (the ghrelin receptor) and triggers a pulse of growth hormone release. That's the whole mechanism, and it's well established in animals. What's thin is the human evidence. Only one controlled human trial has ever tested ipamorelin: a 2014 study in patients recovering from bowel surgery. It did not show a statistically significant benefit [3]. Everything else — sleep, recovery, body composition — comes from small rodent studies, or from people using it outside any clinical trial and reporting what they noticed. Ipamorelin has never been approved as a drug anywhere. It is sold as a research chemical. Nothing below is a recommended dose for a person; every number comes from a specific study, in a specific species. ## What it is Ipamorelin is a synthetic pentapeptide — five amino acids, engineered for stability. It was built by removing two amino acids from an older peptide (GHRP-1) and adding protected residues that resist enzyme breakdown. It selectively activates the ghrelin receptor (GHS-R1a) on pituitary cells. 'Selective' is the key word: earlier growth-hormone-releasing peptides in this class also raised cortisol and prolactin as a side effect. Ipamorelin, at the doses characterized in its founding animal studies, largely does not. That selectivity — not raw potency — is what distinguishes it from its chemical predecessors. ## How it works Ipamorelin's receptor sits on pituitary cells called somatotrophs. When ipamorelin binds it, those cells release a single pulse of growth hormone — not a sustained elevation, a pulse. Human pharmacokinetic data show that pulse peaks about 40 minutes after dosing, with a terminal half-life near two hours [4]. The same receptor also sits on gut and pancreatic tissue, which is why ipamorelin's documented effects extend beyond growth hormone: gut motility, and, in isolated pancreatic tissue, direct insulin release. It's frequently paired in research-use protocols with a GHRH analog because the two act on separate steps of the same axis — GHRH increases GH-cell output capacity, ipamorelin triggers the release. No trial has tested that combination; the pairing is a mechanistic argument, not a tested protocol. ## What the research shows The most recent published study is a 2024 ferret experiment. Ipamorelin reduced chemotherapy-associated weight loss by roughly a quarter during the delayed phase of cisplatin treatment, but produced no anti-emetic effect — it did not reduce vomiting [1]. The only human trial is older and negative. A 2014 Phase 2 RCT gave 114 adults recovering from bowel resection ipamorelin or placebo. Median time to first tolerated meal: 25.3 hours with ipamorelin versus 32.6 hours with placebo. The difference did not reach statistical significance (p=0.15) [3]. Treatment-emergent adverse events were common in both arms, slightly lower with ipamorelin. Human pharmacokinetic data come from a single-dose infusion study in eight healthy volunteers per dose level. Kinetics were dose-proportional; the terminal half-life was about two hours [4]. In rats, 15 days of subcutaneous ipamorelin dose-dependently increased longitudinal bone growth rate, with no measurable change in circulating IGF-1 or bone-turnover markers — suggesting a locally driven effect rather than a systemic one [5]. One more study is worth flagging even though it did not test ipamorelin itself: a 28-day study of a related ghrelin-receptor agonist found dose-dependent heart-muscle damage in rats [2]. That's a class-level signal, not an ipamorelin-specific one — but it's the closest thing this receptor class has to a long-term cardiac safety study. ## Reported effects, cautions & safety People using ipamorelin in research-use communities describe a fairly consistent pattern — anecdotal, not clinical evidence, drawn from self-report alone. Deeper, more restorative sleep is the most frequent claim, often appearing within one to two weeks. Vivid dreams in the early weeks are commonly described too. On the adverse side, a warm facial flush shortly after injection is widely reported, along with occasional tingling in the hands and feet, mild puffiness, and a bump in appetite. None of it is measured, verified, or tied to a known dose. Cited cautions: the cardiovascular signal is the most concrete one available. A 28-day rat study of a related ghrelin-receptor agonist found dose-dependent heart-muscle damage — not in ipamorelin itself, but in the same receptor class [2]. Long-term human cardiac safety data for ipamorelin do not exist. The deeper problem is simply how little human data there is. The entire controlled human record is one short perioperative trial and one single-dose pharmacokinetic study [3][4]. There is no long-term human safety database, and material sold as research-grade ipamorelin carries no pharmaceutical quality assurance — purity and identity are unverified outside a lab you control. ## Where it fits in Research Peptide Fundamentals On a desk organized by trial depth, ipamorelin sits at the bottom. Its mechanism is clean and well characterized in animals [4][5]. Its human trial record is one negative study [3]. Compare that to [tirzepatide](/tirzepatide), which carries a full Phase 3 program and an approved indication, or even [NAD+](/nad), whose precursors have cleared multiple placebo-controlled human trials [7][8][10]. That doesn't make ipamorelin useless as a research subject — the ghrelin-receptor mechanism is real and reproducible [4]. It means the clinical case for it, in humans, has not yet been made. See the [comparison page](/compare) for how all four compounds stack up. --- This is a citation ledger, not a clinic — we report what the trials found and stop there.